Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Francesco Bandello, EURETINA 2022: The Relationship Between OCTA and FA/ICGA in AMD Part 2

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 18th 2022

In this touchOPHTHALMOLOGY interview, Prof. Francesco Bandello (Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele, Milan, Italy) discussed the findings of a study investigating the relationship between optical coherence tomography angiography and fluorescein angiography/indocyanine green angiography in AMD and their implications.

‘Morphological and Functional Relationship Between OCTA and FA/ICGA in AMD’ was presented at EURETINA 2022, 1–4 September 2022 

  1. What were the findings of your study investigating the relationship between optical coherence tomography angiography and fluorescein angiography/indocyanine green angiography in age-related macular degeneration (AMD)? (00:56)
  2. How can these findings be used to improve the characterization of AMD? (02:26)
  3. What questions remain unanswered and what future studies are planned? (03:21)

Disclosure: Francesco Bandello has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed as a highlight of EURETINA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup